ViroGates A/S (CO:VIRO) — Market Cap & Net Worth
Market Cap & Net Worth: ViroGates A/S (VIRO)
ViroGates A/S (CO:VIRO) has a market capitalization of $14.67 Million (Dkr93.75 Million) as of September 17, 2026. Listed on the CO stock exchange, this Denmark-based company holds position #26151 globally and #119 in its home market, demonstrating a -3.81% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ViroGates A/S's stock price Dkr10.10 by its total outstanding shares 9281891 (9.28 Million). Also see VIRO current and non-current assets for a full breakdown of the balance sheet.
ViroGates A/S Market Cap History: 2018 to 2026
ViroGates A/S's market capitalization history from 2018 to 2026. Data shows change from $87.13 Million to $14.67 Million (-22.87% CAGR). Also see VIRO cash flow metrics for how efficiently the company converts equity into cash flow.
ViroGates A/S Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ViroGates A/S's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check ViroGates A/S share price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.68x
ViroGates A/S's market cap is 3.68 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $87.13 Million | $3.32 Million | -$16.99 Million | 26.28x | N/A |
| 2019 | $49.81 Million | $3.58 Million | -$18.80 Million | 13.91x | N/A |
| 2020 | $118.36 Million | $5.35 Million | -$18.74 Million | 22.11x | N/A |
| 2021 | $209.12 Million | $7.66 Million | -$17.66 Million | 27.31x | N/A |
| 2022 | $58.23 Million | $15.20 Million | -$9.65 Million | 3.83x | N/A |
| 2023 | $8.74 Million | $6.99 Million | -$12.10 Million | 1.25x | N/A |
| 2024 | $15.39 Million | $4.90 Million | -$14.35 Million | 3.14x | N/A |
| 2025 | $19.53 Million | $5.31 Million | -$10.40 Million | 3.68x | N/A |
Competitor Companies of VIRO by Market Capitalization
Companies near ViroGates A/S in the global market cap rankings as of September 17, 2026. Review ViroGates A/S tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to ViroGates A/S by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.42 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #229 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #232 globally with a market cap of $107.98 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.42 Billion | $102.03 |
| #229 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $93.75 |
| #232 | Stryker Corporation | NYSE:SYK | $107.98 Billion | $281.50 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
ViroGates A/S Historical Marketcap From 2018 to 2026
Between 2018 and today, ViroGates A/S's market cap moved from $87.13 Million to $ 14.67 Million, with a yearly change of -22.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Dkr14.67 Million | -24.91% |
| 2025 | Dkr19.53 Million | +26.89% |
| 2024 | Dkr15.39 Million | +76.08% |
| 2023 | Dkr8.74 Million | -84.99% |
| 2022 | Dkr58.23 Million | -72.15% |
| 2021 | Dkr209.12 Million | +76.69% |
| 2020 | Dkr118.36 Million | +137.61% |
| 2019 | Dkr49.81 Million | -42.83% |
| 2018 | Dkr87.13 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of ViroGates A/S was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.67 Million USD |
| MoneyControl | $14.67 Million USD |
| MarketWatch | $14.67 Million USD |
| marketcap.company | $14.67 Million USD |
| Reuters | $14.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ViroGates A/S
ViroGates A/S, an in vitro diagnostics company, develops and sells blood tests for measuring chronic inflammation for the healthcare sector. It offers suPARnostic TurbiLatex, a CE-IVD approved particle-enhanced turbidimetric immunoassay for quantitative measurement of suPAR in human plasma; suPARnostic AUTO Flex ELISA kit, a fully quantitative immunoassay designed for accurate and reliable measur… Read more